Elixinol Global Limited announced that Elixinol branded cannabidiol (CBD) products are now available on a prescription basis in the New Zealand market via the www.elixinol.com e-commerce website. The launch follows the passage of New Zealand's Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018, which classifies CBD with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug. Elixinol branded capsules, topicals, and tinctures including liposomes meet the required standard for import into New Zealand. Elixinol has already started to receive prescriptions and is happy to announce the first shipment has now been successfully received in New Zealand.